Many studies have now established that the SWI/SNF chromatin remodelling complexes are involved in activation and repression of a variety of genes. In mammalian cells, these complexes contain the BRM and BRG1 helicase-like proteins that are thought to be responsible for nucleosome remodelling. The proto-oncoprotein SYT, involved in the unique translocation t(X;18) found in synovial sarcoma, is known to interact with human BRM (hBRM), thus providing a link between chromatin remodelling factors and human cancer. In this work, we address how SYT interacts with hBRM and BRG1. We demonstrate that the conserved N-terminal SNH domain of SYT, which is also present in the oncoproteins SYT-SSX, binds to both hBRM and BRG1. We have also found that in vivo the C-terminus transactivation QPGY region of SYT can interact with itself. This results in an amplified interaction with hBRM and highlights a possible regulatory function of this domain in cells.
Introduction
Synovial sarcoma is a highly malignant soft-tissue sarcoma that accounts for about 7-10% of all human soft-tissue sarcomas, and it is primarily seen in patients between the age of 15 and 40 years old (Fisher, 1998; dos Santos et al., 2001) . It can occur in any part of the body and nearly all synovial sarcomas have a specific t(X;18)(p11.2;q11.2) chromosomal abnormality that appears to be independent of tumor location in the body (Smith et al., 1987) . This translocation results in the fusion between the SYT gene on chromosome 18 and SSX1, SSX2 or SSX4 genes on chromosome X; the chimeric genes resulting from the translocation are SYT-SSX1, SYT-SSX2 or SYT-SSX4 (Clark et al., 1994; Crew et al., 1995; de Leeuw et al., 1995; Skytting et al., 1999) . In normal tissues, SYT is ubiquitously expressed during embryogenesis (de Bruijn et al., 1996) and in adults (Clark et al., 1994) . In contrast, SSX transcripts show a very restricted distribution in adult human tissues, and the expression is confined to the testis and at very low levels in the thyroid (Crew et al., 1995; Tureci et al., 1996; Gure et al., 1997) . Both gene products together with the fusion proteins are localized in the nucleus with the exclusion of the nucleoli. However, no DNA-binding domain has been identified in SYT or SSX, and presumably their transcriptional regulatory functions are exerted through interactions with other proteins (Brett et al., 1997; Thaete et al., 1999) .
Recently, it has been reported that SYT-SSX1 is associated with increased expression of cyclin D1 and cyclin A, suggesting a link to the cell cycle (Xie et al., 2002a, b) . It has also been found that SYT alone can interact with the histone acetyl transferase p300 for the regulation of cell adhesion. When cells undergo G1 arrest due to contact inhibition, p300 interacts with SYT in the cell nucleus, suggesting further cell cycle links (Eid et al., 2000) .
The SYT sequence encodes for a protein of 54 kDa that contains three different regions, which may have functional significance (Thaete et al., 1999) : an Nterminal SNH domain (SYT N-terminal homology domain), which is conserved across a range of species (e.g. Brassica, rice, zebra fish, C. elegans); a second central region, that has an unusually high content of methionine (16%); and a transcription activating region named the QPGY domain, which is localized to the Cterminal half of SYT. The latter is known as the QPGY domain, as it is rich in glutamine (Q), proline (P), glycine (G) and tyrosine (Y) residues, with a motif of XXYXX, where a tyrosine is surrounded by at least three X residues that could be Q, P or G (Kato et al., 2002) . Furthermore, the QPGY domain resembles the N-terminal activation region of the EWS/FUS/TLS family of proteins (Delattre et al., 1992; Ohno et al., 1993; Thaete et al., 1999) and is even more closely related to the N-terminal region of the BAF250 protein (also called p270/p250) and its two homologs p250R and hELD/OSA1 (Dallas et al., 1998 (Dallas et al., , 2000 Nie et al., 2000; Hurlstone et al., 2002; Kato et al., 2002) , which all contain a QPGY domain and are also part of the SWI/ SNF chromatin remodelling complexes (Peterson, 1996; Sudarsanam and Winston, 2000) . SYT also contains three SH2-and one SH3-binding motifs, one SH2 located at the N-terminus and the others on the C-terminus side (Koch et al., 1991; Pawson and Gish, 1992; Eid et al., 2000) . In the translocation proteins, one SH2 or all SH2/3 motifs at the C-terminus end are lost. In contrast, SSX proteins have a transcriptional repressing region located at the C-terminus, named SSXRD domain (Lim et al., 1998; Thaete et al., 1999) . Thus, a transcriptional activator domain (the QPGY domain on SYT) and a transcriptional repressor domain (the SSXRD on SSX) have been found to be located together on the SYT-SSX fusion proteins.
We have previously demonstrated that SYT and SYT-SSX interact with human BRM (hBRM), an ATPase found in SWI/SNF complexes (Thaete et al., 1999) . SWI/SNF are a large family of ATP-dependent chromatin remodelling complexes that have been characterized as transcriptional activators or repressors, assisting the transcription machinery or other transcription factors to gain access to target genes. These complexes therefore mediate both activation and repression depending on the activity of the recruited transcriptional regulators (Sudarsanam and Winston, 2000; Muchardt and Yaniv, 2001; Martens and Winston, 2002) .
In mammalian cells, there are two major SWI/SNF complexes, named BAF and PBAF, that have similar functions but distinct compositions (Kwon et al., 1994; Wang et al., 1996a, b; Armstrong et al., 1998; O'Neill et al., 1999; Nie et al., 2000) . BAF contains either one of the two ATPases hBRM or BRG1 (both of which are homologous to the yeast SNF2 protein and the Drosophila Brahma protein), whereas PBAF contains only BRG1 (Nie et al., 2000) . Another signature that confirms distinctness between the two human complexes is the presence of BAF250 protein only in the BAF complex and not in PBAF (Nie et al., 2000) .
Expression of SYT-SSX1 in the 3Y1 rat fibroblast cell line enhances growth rate in culture, anchorage-independent growth in soft agar and tumor-forming potential in nude mice (Nagai et al., 2001) . Furthermore, the same authors showed a functional association between SYT-SSX1 with the chromatin remodelling factor hBRM, producing a link between regulation of chromatin remodelling and cancer. Both studies have therefore shown that endogenous SYT and SYT-SSX are associated with hBRM-containing remodelling complex in vivo.
In this work, we have addressed how SYT interacts with hBRM and BRG1. First, we identified the SNH domain of SYT as the domain involved in the interaction with a conserved domain in the N-terminal region of hBRM. We also found that BRG1 interacts with the SNH domain in a similar manner. Second, we show that SYT is able to form homo-oligomers through the C-terminus QPGY domain.
Results

Identification of domains of interaction between SYT and hBRM
We previously demonstrated that the human homologue of the SNF2/Brahma protein hBRM colocalizes with SYT and SYT-SSX in nuclear speckles when cotransfected into cells, and also interacts with SYT and SYT-SSX in vitro (Thaete et al., 1999) . It was also shown that the N-terminal 181 amino acids of SYT-SSX1 were able to co-precipitate with hBRM (Nagai et al., 2001) . In order to further define the domain/s of interaction between SYT and hBRM, full-length SYT (SYT FL) and various deletion constructs were cloned into the mammalian expression vector pACT in frame with the VP16 activation domain, and full-length hBRM (hBRM FL) was cloned into pBIND in frame with the GAL4 DNA-binding domain. The resulting expression plasmids were cotransfected into COS7 cells together with the reporter pG5luc and the appropriate controls ( Figure 1a) .
We initiated our studies by investigating which domains of SYT were required for its interaction with hBRM. Measurement of the firefly luciferase expression level assessed the interaction between hBRM and the different SYT deletions. The background firefly luciferase value was obtained from cotransfecting GAL4-hBRM FL with the parental vector pACT (VP16); this value has been designated as one activation unit for each transfection shown in the figures. High levels of firefly luciferase were observed when GAL4-hBRM FL was cotransfected with VP16-SYT FL, SYT E or D, where constructs VP16-SYT E and D, in addition to the N-terminal SNH domain, each contains different sequences of the QPGY-rich repeat region of the QPGY domain ( Figure 1a ). Low levels of activation were reproducibly detected with the C-terminal deletion VP16-SYT C that contained only the SNH domain and the methionine-rich central region (Figure 1a ). In contrast, in the two N-terminal deletions of SYT, VP16-SYT A and VP16-SYT B, which retain the full C-terminal QPGY domain but not the SNH domain, firefly luciferase expression was not enhanced above background levels ( Figure 1a ). Taken together, these results suggest that the N-terminal SNH domain of SYT is required for the binding to hBRM, but the C-terminal QPGY domain, although it does not interact on its own with hBRM, could possibly play a role in enhancing the interaction since levels of activation are considerably increased when the entire or partial QPGY domain is present. The fact that VP16-SYT E and D contain different partial sequences of the QPGY repeat domain is indicative that the number of repeats along the sequence could be more important for the interaction than a specific sequence within the overall domain. Therefore, the strength of the interaction could be proportional to the number of repeats since the luciferase expression values increased proportionally to the length of the QPGY domain. The GAL4-hBRM FL was also tested in conjunction with VP16-SYT-SSX2 FL and in parallel to the VP16-SYT FL and deletion constructs. Interestingly, no activation of the reporter promoter was observed in the assay with the SYT-SSX2 construct, which indicated that the SSXRD present in the fusion could completely abolish the SYT activation observed in the same assay (Figure 1a) . The specificity of these interactions is shown by the fact that GAL4-hBRM FL does not interact with VP16-MyoD (Figure 1a) . Similarly, GAL4-ID with VP16-SYT FL, VP16-SYT deletions and VP16-SYT-SSX2 also give background values (data not shown). It should be noted that the interaction of SYT with hBRM is very strong, approximately, 3.5-fold higher than GAL4-ID/VP16-MyoD interaction used as the positive control ( Figure 1a) .
Next, we investigated the interaction of SYT FL with deletion constructs of hBRM ( Figure 1b) . The results have shown that a construct lacking the N-terminal 131 amino acids of hBRM is unable to bind to SYT, confirming previous results that have demonstrated that the amino acids 156-205 are involved in the interaction with SYT (Nagai et al., 2001) . Our results also showed that the other hBRM domains are not involved in the interaction. The specificity of the assay is demonstrated by cotransfection of GAL4-hBRM FL along with VP16-MyoD, which shows only background values ( Figure 1b ). The region of hBRM involved in SYT binding corresponds to a conserved sequence that in the yeast SNF2/SWI2 protein (the yeast homolog of hBRM and BRG1) binds to a protein named SNF11. SNF11 is a 19 kDa yeast protein that can act as transcriptional activator, although its cellular function is still unknown.
SNH N-terminal domain of SYT protein interacts with the SNF11 N-terminal domain of hBRM and BRG1 in vitro
To confirm and further delineate the binding domains of SYT and hBRM, we performed in vitro pull-downs using GST recombinant proteins and radiolabelled in vitro translated protein fused with different epitope tags. We have previously found in GST pull-downs that SYT (and SYT-SSX) interacts with the N-terminal 187 amino acids of hBRM (Thaete et al., 1999) . In the experiment shown here (Figure 2a ), we narrowed down the region of SYT required to interact with hBRM to the N-terminal SNH domain (amino acids 15-75). Using the GSThBRM SNF11 BD construct (amino acids 158-214), it can be seen that the SNH domain of SYT interacts with the SNF11-binding domain of hBRM. Furthermore, SYT FL also interacts with GST-hBRM SNF11 BD in agreement with the results in the transfected 293T cell line (Nagai et al., 2001 ) and with GST-BRM N-terminal used as a positive control (Figure 2a ). In contrast, pulldowns with GST-BRM C-terminal do not show any interaction with SYT FL and SYT SNH domain, ruling out nonspecific interactions with the beads (Figure 2a ). We also tested BRG1 SNF11 BD (amino acids 156-211) (Treich et al., 1995) , which has 73% homology with hBRM SNF11 BD. We wanted to investigate if the difference in amino-acid sequence between the two proteins could change the binding affinity with the SNH domain of SYT. Our results show that the SNF11 BD of BRG1 also binds the SYT SNH domain and the strength of the two interactions, based on band quantification (ImageQuant 5.0 software) of three independent GST pull-downs, is the same (Figure 2b ).
In a similar experiment in which the GST fusion proteins were replaced by proteins containing His-tag epitopes, we tested whether the QPGY domain of SYT might also bind to the SNF11 BD of hBRM directly in order to explain the enhancing effect of the QPGY domain ( Figure 1a ). In this experiment, 35 S-labelled SYT fragments or full-length SYT-SSX2 were expressed as VP16 domain fusion proteins in vitro and then mixed with in vitro translated and labelled His-tagged SNF11 BD or His-RNA BD of SIP protein as a negative control. Cobalt beads (Talon) were then added and binding of labelled protein was determined by SDS-PAGE ( Figure 3) . The results confirm the interaction between SNF11 BD and SYT N-terminal ( Figure 3 , lane 4). A positive interaction was also observed between SNF11 BD and SYT-SSX2 FL underlining evidence that the lack of activation of the reporter promoter seen between GAL4-hBRM and VP16-SYT-SSX2 in the mammalian two-hybrid assay is likely due to the repression activity of the SSX region in the fusion rather than lack of ability to bind hBRM (compare Figure 1a to Figure 3 , lane 6). In this experiment, however, the QPGY domain was shown not to interact with the hBRM SNF11 BD in vitro ( Figure 3 , lane 5); the same result was obtained using hBRM FL (data not shown).
These experiments taken together with the mammalian two-hybrid assays (Figure 1a and b) confirmed the direct interaction between SYT SNH domain and hBRM SNF11 BD and reveal a possible indirect role of the QPGY domain of SYT in the interaction.
SYT forms homo-oligomers through its QPGY domain
It has been shown previously by immunofluorescence studies that GFP protein fused with SYT and SYT-SSX localized in discrete speckles in the cell nucleus (Brett et al., 1997; Soulez et al., 1999; Thaete et al., 1999) . In a preliminary experiment, we observed that cotransfection of GFP-SYT QPGY and GAL4-SYT QPGY shows colocalization of speckles in the nucleus and in the cytoplasm (Figure 4 ) (the C-terminus SYT QPGY constructs used in this experiment do not contain a nuclear localization signal that is located at the N-terminus end of SYT) (dos Santos et al., 2000) . Interestingly, the GAL4-SYT QPGY is confined in the cell nucleus (due to the GAL4 nuclear localization signal) only when coexpressed with the negative control GFP (Figure 4 , row C), but in the presence of GFP-SYT QPGY (that lacks the nuclear localization signal) its pattern distribution changes. Despite the GAL4 nuclear localization signal, we observed GAL4-SYT QPGY also outside the nuclear boundary and this entirely colocalizes with GFP-SYT QPGY speckles. This suggests that the two tagged proteins do not colocalize simply because they have identical QPGY domains, and that GFP-SYT QPGY may interact with GAL4-SYT QPGY. This experiment therefore suggests that SYT could interact with itself through its QPGY domain, and this oligomerization gives rise to the speckles.
To further investigate this hypothesis, SYT FL was cloned into pBIND vector and tested in the mammalian two-hybrid assay with either VP16-SYT FL or VP16-SYT deletion constructs (Figure 5a and b) . This experiment shows high luciferase values when VP16-SYT FL, SYT A and SYT B were assayed. Moderate interaction was seen with constructs SYT E and D, whereas SYT C (containing just the N-terminus region) resulted in only background levels (Figure 5a ). These results suggest that SYT is able to form homo-oligomers where two or more SYT units interact together via their C-terminus QPGY domain. To gain further evidence for this interaction, a fragment comprising only this section of the protein GAL4-SYT H was subcloned into pBIND and tested with VP16-SYT B, retaining only the QPGY domain, and VP16-SYT C, containing the SNH domain and the methionine-rich region as a negative control (Figure 5b ). The luciferase values confirmed the previous result leading to the conclusion that only part of the protein involved in the oligomerization is the QPGY domain of SYT.
The results shown in Figure 5a and b take into consideration the intrinsic SYT transcriptional activation domain that is present in the C-terminal part of the S-methioninelabelled in vitro translated His-SNH domain and SYT FL. In vitro expressed and labelled His-tag only and luciferase protein were used as negative controls. Specific binding of GST-SNF11 BD to SYT SNH domain (lane 5) and SYT full length (lane 7) is observed; similar results were detected as well when GST-N BRM was used instead of GST-SNF11 BD (lanes 10 and 11, respectively). (b) Bacterially produced GST-hBRM-SNF11 BD and GST-BRG1-SNF11 BD were purified with glutathione-sepharose beads and incubated with 35 S-methionine-labelled in vitro translated His-SNH domain and His-hBRM-SNF11 BD, the latter used as a negative control. Specific binding is observed between SYT SNH domain and hBRM SNF11 BD (lane 8) as well as BRG1 SNF11 BD (lane 10). The band observed in lane 6 is due to a weak interaction observed between the SNH domain and GST alone. This binding affinity has been measured to be on average about 10 times weaker when compared to the SNH-binding affinity with GST-hBRM SNF11 BD and GST-BRG1 BD (compare lane 6 to 8 and 10) protein (Brett et al., 1997) . These values are shown as the background activation level and only results above this threshold (dashed line) have been considered as positive interactions. It should be pointed out that when the N-terminal domain is removed (amino acids 1-159), the remaining part of the SYT protein has a markedly increased activation ability compared to the full-length construct (compare transfection 1 in Figure 5b to 1 in Figure 5a ). This increased ability to activate transcription in vitro when the QPGY domain of SYT alone is used has been observed previously (Thaete et al., 1999 ), but has not been further investigated.
SYT homo-oligomerises in transfected COS7 cells
To further demonstrate an interaction of the QPGY domain of SYT with itself, COS7 cells were cotransfected with plasmids encoding for VP16-SYT QPGY and GAL4-SYT QPGY (Figure 6a) . Extracts from the transfected COS7 cells were then immunoprecipitated with anti-VP16 monoclonal antibody and the immunoprecipitate analysed by Western blot using the rabbit polyclonal anti-SYT 903 antibody. As a negative control, an identical immunoprecipitation was performed with anti-GFP monoclonal primary antibody. Total cell lysate was also substituted with buffer and used for immunoprecipitation with anti-VP16 and anti-GFP to detect bands that are due to cross-reaction between rabbit and mouse antibodies. Anti-VP16 antibody co-precipitated VP16-SYT QPGY with GAL4-SYT QPGY. No SYT-QPGY proteins were brought down in control immunoprecipitations where GFP monoclonal antibody had been used in substitution of VP16 antibody, demonstrating specificity. In order to confirm the specificity of the anti-SYT 903 antibody, we performed a competition experiment with anti-SYT 903 antibody in the presence of nonspecific and specific antigen peptides (Figure 6b ). When anti-SYT 903 antibody was incubated in the presence of the specific SYT antigen peptide (peptide 508), the specific bands disappeared, but not when a different peptide was used as negative control (peptide 510). The results clearly show that the QPGY domain of SYT is able to coprecipitate in vivo with itself. In the peptide competition experiment, an extra band of 54 kDa is also competed away, migrating just above the antibody heavy-chain band, and this corresponds to the molecular weight of the endogenous SYT.
We were unable to demonstrate that the QPGY domain of SYT interacts with itself in vitro when we used proteins synthesized in Escherichia coli and in in vitro translation systems (data not shown). To further investigate the in vitro interaction of VP16-SYT QPGY with GAL4-SYT QPGY, the two proteins were separately expressed in mammalian COS7 cells and immunopurified using VP16 and GAL4 tags. GAL4-SYT QPGY was then eluted from the conjugated protein G beads and incubated with the VP16-SYT QPGY beads under in vitro binding conditions. In vitro co-precipitation was then performed through the VP16 tag. After washing, the bead-bound proteins were analysed by Western blot. In this experiment, we successfully coprecipitated the immunopurified proteins and the SYT QPGY oligomerization was thus confirmed to occur in vitro (Figure 7a , lane 6). All the above coimmunoprecipitations were carried out in the presence of phosphatase inhibitors. In view of high content of tyrosine residues in the QPGY domain, we also analysed whether phosphorylation was required for this interaction. The experiment was carried out in parallel with the in vitro co-precipitation shown in Figure 7a , lane 6. In this case, the immunopurified proteins were incubated with l protein phosphatase (l-PPase) and then immunoprecipitated. Western blot of the co-precipitation, probed with the SYT 903 antibody, revealed that the interaction between VP16-SYT QPGY and GAL4-SYT QPGY is not affected by l-PPase treatment (Figure 7a, lane 7) . To confirm this result, cell lysates from cotransfected COS7 cells were treated with l-PPase until complete dephosphorylation had occurred (data not shown) and used for immunoprecipitation (as for experiment of Figure 6a ), together with an untreated cell lysate as positive control. Figure 7b , lanes 1 and 2, once again shows that there is no difference in the interaction of VP16-SYT QPGY and GAL4-SYT QPGY without (lane 1) and with (lane 2) l-PPase treatment. Thus, according to our data, phosphorylation does not appear to play a role in the SYT QPGY homo-oligomerization. In confirmation with this result is the fact that when the SYT interacts with hBRM and BRG1 and form homo-oligomers M Perani et al phosphorylation status of GAL4-SYT QPGY and VP16-SYT QPGY was checked before and after coimmunoprecipitations by Western blots, using rabbit antiphosphorylated proteins and rabbit antiphosphotyrosine antibodies, no significant phosphorylated bands were detected when compared to the untransfected cell lysate (data not shown).
Discussion
In this report, we defined the domain of SYT that interacts with the N-terminal SNF11-binding domain of the human helicase hBRM and its homolog BRG1. The domain corresponds to amino acids 15-75 encompassing the conserved SNH domain. The SNH domain (SYT N-terminal homology domain) was first identified because it shares significant similarities with protein sequences from plants, nematodes and fish, as well as mammals (Thaete et al., 1999; de Bruijn et al., 2001) . This similarity across a broad range of species might imply a functional significance to the region and this is the second time that a target protein has been identified that interacts specifically with this domain. The AF10 protein, which is a putative transcription factor deregulated in t(10;11)-positive acute leukemias, was also found to interact with the SYT SNH domain .
The N-terminal SNF11-binding domain of hBRM and BRG1 is so called after the yeast SNF11 protein which is an integral component of the yeast SVI/SNF complex and interacts with SNF2/SWI2, the yeast homolog of hBRM and BRG1 (Treich et al., 1995) . SYT and SNF11 seem therefore to bind to the same sequence but in two different species. However, although they have similar binding abilities and also transcriptional activation properties, there is no sequence similarity that might suggest a comparable function in the two species. Although the SNF11 BD of hBRM and BRG1 differ by 27% in the amino-acid sequence, their diversity does not appear to affect the binding affinity with the SNH domain of SYT, as measured by ImageQuant quantification software (Figure 2b) . Therefore, the most conserved parts between the hBRM and BRG1 sequences are likely to be involved in the interaction. Based on secondary structure predictions using nine different analyses (Combet et al., 2000) , this conserved region appears to be alpha helix folded, in contrast to the flanking regions that are mainly predicted to be random coil sequences.
The alpha helix prediction corresponds to amino acids 178-199 for hBRM and amino acids 176-197 for BRG1. The SNF11-binding domain used in our SYT-binding experiments corresponds to amino acids 158-214 for hBRM and to amino acids 156-211 for BRG1. Our previous results (Thaete et al., 1999) indicated that in vitro hBRM also binds to SYT-SSX2 with a similar affinity to SYT in agreement with our present results ( Figure 3 ) and with the endogenous association showed previously between hBRM and SYT-SSX1 (Nagai et al., 2001) . Therefore, it is likely that in the mammalian two hybrid, the inability of cotransfected GAL4-hBRM and VP16-SYT-SSX to activate the luciferase reporter is due to the SSXRD that prevails over the QPGY activation region of SYT and the VP16 activation domain (Figure 1a ). This could imply that, in cells, if SYT-SSX still interacts with identical target proteins to SYT, the repression region of SSX could alter the physiological function of SYT leading to misregulation of gene expression.
GAL4-SYT FL & VP16-SYT constructs Transfections
The mammalian two-hybrid results suggested that the QPGY domain of SYT could play a role in enhancing the interaction with hBRM. In the presence of hBRM FL, we observed that in SYT constructs containing both the SNH and the QPGY domains, the latter strongly increases the mammalian two-hybrid luciferase values when compared to SYT lacking the QPGY domain, that is, construct SYT C (Figure 1a , compare transfections 1, 5 and 6 to 4). If we compare the fold activation value of 6.7 by SYT C (SYT N-terminal domain) in transfection 4 to the SYT constructs containing full or partial QPGY sequences (transfections 1, 5 and 6), we observe the fold activation value increase of 28 times (compare transfection 4 to 6), 102 times (compare transfection 4 to 5) or 145 times with SYT FL (compare transfection 4 to 1). Therefore, with the intention of investigating how the QPGY domain is involved in the interaction with hBRM, we found that there is no direct interaction between the QPGY domain and hBRM, but interestingly we discovered that SYT can interact with itself through the QPGY domain. In the light of our new findings, the enhanced signal seen in the mammalian two-hybrid experiments due to the presence of the QPGY domain could be explained as a result of the SYT QPGY oligomerization, which amplifies luciferase values of the reporter (Figure 1 ). In view of high content of tyrosine residues in the QPGY domain, we analysed whether phosphorylation could regulate this interaction. Treatment of cell lysates with l-PPase did not affect coimmunoprecipitation of VP16-SYT QPGY with GAL4-SYT QPGY. Similarly, when the two proteins were expressed and immunopurified separately, phosphatase treatment did not affect the ability of the two proteins to interact with one another. Therefore, by mammalian two-hybrid assay, in vivo and in vitro coimmunoprecipitations, we have shown that in transfected cells, the QPGY domain can form homooligomeric proteins and this ability is independent of the phosphorylation status of the QPGY domain. It is possible that in vivo SYT binds as an oligomer to the SWI/SNF complexes. Following recruitment of such complexes to the SWI/SNF-regulated promoters, the function of the oligomeric QPGY activation domain could then be to stimulate transcription of target genes.
Materials and methods
Plasmid description and construction
Mammalian two-hybrid vectors pBIND and pACT were used in the CheckMate Mammalian Two-Hybrid assays (Promega). Each construct was derived from pBluescriptIISK-SYT FL and HA-hBRM FL, kindly donated by Christian Muchart. The vectors pET30 (Novagen) and pGEX-4T-1 (Amersham Biosciences) were used to clone His and GST fusion genes for in vitro interactions assays. Each clone was generated by PCR using Pfu polymerase (Stratagene). For GST-hBRM SNF11 BD (amino acids 158-214) and GST-BRG1 SNF11 BD (amino acids 156-211), the sequences were amplified and ligated using BamHI/EcoRI restriction sites. Amino-acid lengths and positions for each construct are always indicated in the figures.
Antibodies and immunoprecipitations
Polyclonal anti-SYT 903 antibody was raised by immunizing rabbits with a synthetic peptide (YSGQEDYYGDQYS-HGG þ C) from the C-terminal region of SYT (Eurogentec) coupled to KLH (keyhole limpet hemocyanin). Antiserum was finally affinity purified using the specific peptide crosslinked to the SulfoLink Coupling Gel (Perbio), and tested for specificity by immunoblotting and peptide competition. Commercially available antibodies used for Western blots analysis were: anti-VP16 activation domain clone 2GV-4 mouse monoclonal (Euromedex), anti-GAL4 DNA BD mouse monoclonal (Clontech), anti-GAL4 agarose conjugate mouse monoclonal (Santa Cruz Biotechnology), antiphosphorylated proteins (Pan) rabbit polyclonal (Zymed Laboratories) and antiphosphotyrosine rabbit polyclonal (Calbiochem). Whole-cell lysates of transfeced and untrasfected COS7 cell were obtained using mammalian protein extraction reagent (M-PER) (Perbio) according to the manufacturer's instructions. For the immunoprecipitations, whole-cell lysates in the presence of protein inhibitors (Roche) and phosphatase inhibitors (0.2 mM PMSF, 1 mM sodium fluoride, 0.1 mM sodium orthovanadate and 10 mM glycerol phosphate) were incubated with the appropriate antibodies for 1 h at 41C and for further 3 h after 50 ml of 50% (vol/vol) protein Gsepharose (Sigma; pre-equilibrated in PBS buffer) were added. Protein G beads were collected by centrifugation and the pellets were washed five times in cold PBS buffer. Samples were analysed by protein electrophoresis.
Dephosphorylated cell lysates were prepared using l-PPase (New England BioLabs). Cell lysates were incubated for 4 h at 301C with 8 U/ml in the presence of 2 mM MgCl 2 , and fresh SYT interacts with hBRM and BRG1 and form homo-oligomers M Perani et al phosphatase was added at each hour from the start. Successful dephosphorylation of endogenous proteins and protein stability was checked by Western blots using antiphosphorylated proteins (Pan) rabbit polyclonal (Zymed Laboratories), antiphosphotyrosine rabbit polyclonal (Calbiochem) and anti-SYT 903 rabbit polyclonal.
Immunopurification and in vitro interaction of GAL4-SYT QPGY and VP16-SYT QPGY from transfected cells lysates GAL4-SYT QPGY and VP16-SYT QPGY were immunopurified from cell lysates from separately transfected COS7 cells using anti-VP16 activation domain clone 2GV-4 mouse monoclonal (Euromedex) with protein G-sepharose (Sigma) and anti-GAL4 agarose conjugate mouse monoclonal (Santa Cruz Biotechnology). Protein beads were collected by centrifugation and the pellets were washed five times in cold PBS buffer. GAL4-SYT QPGY was then eluted from the beads three times using 30 ml IgG elution buffer pH 2.5-3.0 (Perbio), and the extract was immediately neutralized with 2.5 ml of 2 M Tris solution pH 10. The eluted protein was passed through a Spin-X Centrifuge Tube Filter containing a cellulose acetate membrane of 0.22 mm pore diameter (Corning Incorporated) to avoid any contamination with residual GAL4 conjugate beads. The protein was then diluted five times in M-PER buffer (Perbio) and added to the purified VP16-SYT QPGY protein bound to the beads. When proteins were dephosphorylated, the immunopurified proteins were incubated with 8 U/ml of l-PPase (New England BioLabs) in the presence of 2 mM MgCl 2 for 2 h at 301C. Immunoprecipitations were then carried out at room temperature in the presence or absence of 8 U/ml of l-PPase added to the immunoprecipiation buffer in the presence of 2 mM MgCl 2 . Fresh phosphatase was then added at each hour. The conditions for the l-PPase treatment were those found to dephosphorylate cell lysate proteins. Beads were collected by centrifugation after 4 h incubation and washed five times in cold PBS buffer. Bound proteins were eluted and analysed by Western blots.
Immunoblot analysis
Proteins from whole-cell lysates and immunoprecipitations were analysed by NuPage 4-12% Bis-Tris SDS-polyacrylamide gels electrophoresis (Invitrogen) and transferred onto an Immobilon-P PVDF membrane (Millipore). Blots were incubated with the indicated primary antibody and then with the species-specific horseradish peroxidase-conjugated secondary antibody (Bio-Rad) and bands detected by chemiluminescence (ECL detection reagents, Amersham Biosciences).
Peptide competition
Competition experiments were performed by preincubating the antibodies with their specific or nonspecific antigen peptide at a final concentration of 35 mM for 2 h at 41C (Mason et al., 1999) .
Transfections and two-hybrid assays
The CheckMate Mammalian Two-Hybrid dual reporter firefly/renilla luciferase assay (Promega) was used to detect protein-protein interactions. For each transfection, different combinations of plasmid DNA of the mammalian vectors pBIND and pACT (Promega) expressing full-length or deletions constructs of SYT and hBRM were transfected together with the luciferase reporter vector pG5luc according to the protocol. The pG5luc vector has five UAS DNAbinding sites upstream of a TATA box, which in turn is upstream of the firefly luciferase gene. Duplicate transfections were carried out in COS7 cells (monkey kidney fibroblast) using six-well plates and Supefect reagent (QIAGEN) as described by the manufacturer. The experiments were repeated at least three times independently and the plasmids pBIND-Id and pACT-MyoD (provided by Promega) were used together as positive controls and singly as negative controls. Firefly luciferase values were obtained using a Microtiter Plate Luminometer (DYNEX). Results were normalized for transfection efficiency by the use of coexpressed renilla luciferase gene located on the pBIND vector, and for levels of protein expression by Western blot analysis to control for variations in protein expression level of transfected constructs. Blots were probed with anti-SYT 903, anti-VP16, anti-hBRM and anti-GAL4 antibodies as described previously. To standardize the immunoblotting signals, all blots were probed for b-actin using anti-b-actin AC-15 antibody (Abcam).
In vitro interactions assays
35 S-labelled proteins were generated using TnT T7 quickcoupled transcription/translation system (Promega). Pulldowns with in vitro 35 S-radiolabelled proteins were performed in 500 ml of immunoprecipitation buffer consisting of 100 mM NaCl, 5 mM MgCl 2 , 10 mM Tris pH 7.5 and 0.1% Triton X-100. In each pull down, the proteins were mixed together as indicated in the figures, incubated for 4 h at 41C and precipitated using Talon beads according to the manufacturer's instructions (Novagen). For GST pull-down assays, GST-hBRM SNF11 BD, GST-BRG1 SNF11 BD, GSThBRM NT, GST-hBRM CT and GST-SYT full length were expressed in E. coli BL21star(DE3)pLysS (Invitrogen) and purified as described previously (Thaete et al., 1999) . GST proteins in glutathione-sepharose 4B beads (Amersham Biosciences) were incubated at 41C for 1 h in 500 ml immunoprecipitation buffer with the 35 S-radiolabelled in vitro translated protein as indicated in the figures. The beads were washed six times with the above buffer and then loaded onto 4-12% Bis-Tris SDS-polyacrylamide gels.
Transfections and immunofluorescence assays
Transfections were performed as described in 24-well plates using Superfect reagent (QIAGEN). Confocal microscopy was carried out as previously described (Thaete et al., 1999) . GAL4-SYT QPGY and GAL4 were detected with anti-GAL4 monoclonal antibody sc-510 (Santa Cruz Biotechnology). Slides were imaged with a Leica TCS SP confocal microscope. Controls were carried out to ensure there was no bleedthrough between green (GFP) and red (Alexa 568) signals. In addition, cells transfected with GFP-labelled constructs alone were labelled using anti-GAL4 antibody and Alexa 568 to check that the anti-GAL4 antibody did not detect transfected GFP-SYT QPGY.
